Karyopharm Therapeutics
KPTI
117 hedge funds and large institutions have $64.2M invested in Karyopharm Therapeutics in 2023 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 25 increasing their positions, 41 reducing their positions, and 23 closing their positions.
1,654% more call options, than puts
Call options by funds: $456K | Put options by funds: $26K
0.18% less ownership
Funds ownership: 4.5% → 4.33% (-0.18%)
1% less funds holding
Funds holding: 118 → 117 (-1)
4% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 23
38% less capital invested
Capital invested by funds: $103M → $64.2M (-$38.6M)
39% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.59M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.49M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.14M |
| 4 |
Renaissance Technologies
New York
|
+$1.11M |
| 5 |
Morgan Stanley
New York
|
+$580K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$2.38M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
-$1.87M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.86M |
| 4 |
BlackRock
New York
|
-$912K |
| 5 |
PL
Parkwood LLC
Cleveland,
Ohio
|
-$661K |
KPTI Hedge Fund Activity: Q4 2023 in Review
117 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2023, worth a combined $64.2M — down 38% from $103M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of KPTI and 22 opened new positions — a net loss of 1 holder — while 41 trimmed existing stakes and 25 added.
The largest buyer was GSA Capital Partners, adding an estimated $1.59M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $2.38M sold.
- 117 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2023, down from 118 in Q3 2023.
- Funds reported $64.2M of Karyopharm Therapeutics stock for Q4 2023, down 38% quarter-over-quarter.
- 22 funds opened new Karyopharm Therapeutics positions in Q4 2023 and 23 closed out, a net change of -1 holder.
- The largest Karyopharm Therapeutics buyer in Q4 2023 was GSA Capital Partners, an estimated $1.59M added.
- The largest Karyopharm Therapeutics seller in Q4 2023 was AIGH Capital Management, an estimated $2.38M sold.
Based on aggregated 13F filings for Q4 2023.